Article
Post-Progression Survival in Secondary EGFR T790M-Mutated Non-Small-Cell Lung Cancer Patients With and Without Osimertinib After Failure of a Previous EGFR TKI.
Targeted oncology - 1 Aug 2020
Chiang Chi-Lu, Huang Hsu-Ching, Shen Chia-I, Luo Yung-Hung, Chen Yuh-Min, Chiu Chao-Hua
Abstract excerpt
BACKGROUND: Osimertinib is effective in non-small-cell lung cancer (NSCLC) with an acquired epidermal growth factor receptor (EGFR) T790M mutation, the most common resistance mechanism to first- and second-generation EGFR tyrosine kinase inhibitors (TKIs). OBJECTIVES: We aimed to evaluate survival outcome of patients with EGFR-mutant NSCLC who have progressed on previous EGFR TKI therapy. PATIENTS AND METHODS:...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.